Mapping DNA and RNA changes in Acute Myeloid Leukemia at the single-cell level
Official title: High-throughput single-cell joint RNA and DNA methylation mapping of Acute Myeloid Leukemia
Funded at Icahn School of Medicine at Mount Sinai · NIH-11062605 · Data updated 2026-11-12
This study is looking at how changes in DNA and gene activity affect Acute Myeloid Leukemia (AML), using a new technique to examine individual cells, which could help doctors find better ways to diagnose and treat the disease just for you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | March 1, 2025 |
| Project end | February 29, 2028 |
| Funding year | 2025 |
| Award (this year) | $237,023 |
| NIH project number | 1R61CA297881-01 |
| Project ID | NIH-11062605 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Acute Myeloid Leukemia who are seeking advanced treatment options.
✕Less likely to help
Patients with other types of leukemia or those without a diagnosis of Acute Myeloid Leukemia may not benefit from this research.
What this research studies
This research focuses on understanding how changes in DNA methylation and gene expression contribute to Acute Myeloid Leukemia (AML). By developing a new method called SHARE-ME-seq, the team aims to analyze individual cells to uncover the complex interactions between DNA methylation and gene regulation. This approach will help identify specific patterns that are characteristic of AML, potentially leading to better diagnostic and treatment strategies. Patients may benefit from insights gained about their disease at a cellular level, which could inform personalized treatment options.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for patients with Acute Myeloid Leukemia.
How similar studies have gone: Previous research has shown promise in using single-cell technologies to understand cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Ma, Sai — Icahn School of Medicine at Mount Sinai
- Study coordinator: Ma, Sai
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.